Stockholders Vote to Elect Madhavan Balachandran to Board of Directors
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company, announced the election of Madhavan (Madhu) Balachandran to its Board of Directors at the annual stockholders meeting. Balachandran brings over 40 years of experience in manufacturing and operations to Replimune's board. He previously served as Executive Vice President of Operations at Amgen Inc., overseeing global operations. CEO Sushil Patel expressed enthusiasm about Balachandran's addition, citing his valuable experience in commercial development, manufacturing, and operations as assets for Replimune's commercialization preparations. Balachandran's background includes senior operations positions at Burroughs Wellcome Co. and an extensive educational background in chemical engineering and business administration.
Replimune Group, Inc. (Nasdaq: REPL), un'azienda biotecnologica in fase clinica, ha annunciato l'elezione di Madhavan (Madhu) Balachandran nel suo Consiglio di Amministrazione durante l'annuale assemblea degli azionisti. Balachandran porta oltre 40 anni di esperienza nella produzione e nelle operazioni al consiglio di Replimune. In precedenza, ha ricoperto il ruolo di Vice Presidente Esecutivo delle Operazioni presso Amgen Inc., supervisionando le operazioni globali. Il CEO Sushil Patel ha espresso entusiasmo per l'aggiunta di Balachandran, citando la sua preziosa esperienza nello sviluppo commerciale, nella produzione e nelle operazioni come risorse per i preparativi di commercializzazione di Replimune. Il background di Balachandran comprende posizioni dirigenziali nelle operazioni presso Burroughs Wellcome Co. e un'ampia formazione educativa in ingegneria chimica e gestione aziendale.
Replimune Group, Inc. (Nasdaq: REPL), una empresa de biotecnología en fase clínica, anunció la elección de Madhavan (Madhu) Balachandran a su Junta Directiva en la reunión anual de accionistas. Balachandran aporta más de 40 años de experiencia en manufactura y operaciones al consejo de Replimune. Anteriormente, se desempeñó como Vicepresidente Ejecutivo de Operaciones en Amgen Inc., supervisando las operaciones globales. El CEO Sushil Patel expresó su entusiasmo por la incorporación de Balachandran, citando su valiosa experiencia en desarrollo comercial, manufactura y operaciones como activos para los preparativos de comercialización de Replimune. La trayectoria de Balachandran incluye posiciones senior en operaciones en Burroughs Wellcome Co. y una amplia formación académica en ingeniería química y administración de empresas.
Replimune Group, Inc. (Nasdaq: REPL), 임상 단계의 생명공학 회사가 연례 주주 총회에서 Madhavan (Madhu) Balachandran을 이사회에 선출했다고 발표했습니다. Balachandran은 Replimune 이사회에 40년 이상의 제조 및 운영 경험을 제공합니다. 그는 이전에 Amgen Inc.의 운영 부사장으로 재직하며 글로벌 운영을 감독했습니다. CEO Sushil Patel은 Balachandran의 합류에 대한 열정을 표현하며, 그의 상업 개발, 제조 및 운영에서의 귀중한 경험이 Replimune의 상업화 준비에 자산이 될 것이라고 언급했습니다. Balachandran의 배경에는 Burroughs Wellcome Co.에서의 고위 운영직과 화학 공학 및 경영학에 대한 폭넓은 교육적 배경이 포함되어 있습니다.
Replimune Group, Inc. (Nasdaq: REPL), une entreprise de biotechnologie en phase clinique, a annoncé l'élection de Madhavan (Madhu) Balachandran à son conseil d'administration lors de l'assemblée annuelle des actionnaires. Balachandran apporte plus de 40 ans d'expérience en fabrication et opérations au conseil de Replimune. Auparavant, il a occupé le poste de Vice-Président Exécutif des Opérations chez Amgen Inc., supervisant les opérations mondiales. Le PDG Sushil Patel a exprimé son enthousiasme concernant l'ajout de Balachandran, citant son expérience précieuse en développement commercial, fabrication et opérations comme des atouts pour les préparatifs de commercialisation de Replimune. Le parcours de Balachandran inclut des postes de direction dans les opérations chez Burroughs Wellcome Co. et une vaste formation académique en ingénierie chimique et en administration des affaires.
Replimune Group, Inc. (Nasdaq: REPL), ein biopharmazeutisches Unternehmen in der klinischen Phase, gab die Wahl von Madhavan (Madhu) Balachandran in ihren Vorstand während der jährlichen Hauptversammlung der Aktionäre bekannt. Balachandran bringt mehr als 40 Jahre Erfahrung in der Fertigung und im Betrieb in den Vorstand von Replimune ein. Zuvor war er als Executive Vice President für Operationen bei Amgen Inc. tätig und überwachte die globalen Operationen. CEO Sushil Patel äußerte sich begeistert über Balachandrans Hinzufügung und führte seine wertvolle Erfahrung in der kommerziellen Entwicklung, Herstellung und im Betrieb als Bereicherung für die Kommerzialisierungsvorbereitungen von Replimune an. Balachandrans Hintergrund umfasst leitende operativen Positionen bei Burroughs Wellcome Co. sowie eine umfangreiche akademische Ausbildung in Chemieingenieurwesen und Betriebswirtschaft.
- Addition of experienced industry executive to the Board of Directors
- Strengthening of commercial development and operations expertise
- Preparation for potential future commercialization
- None.
WOBURN, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Madhavan (Madhu) Balachandran was elected to Replimune’s Board of Directors at the Company’s annual meeting of stockholders.
“We are thrilled to welcome Madhu to Replimune’s Board of Directors,” said Sushil Patel, Ph.D., Chief Executive Officer of Replimune. “Madhu is an accomplished life sciences industry executive with decades of valuable experience in commercial development, manufacturing and operations. We look forward to working with Madhu as we continue to prepare for commercialization and believe his addition will further strengthen our Board.”
Mr. Balachandran is a biopharma industry executive and has more than 40 years of experience in manufacturing and operations. He was previously with Amgen Inc., where he served as Executive Vice President of Operations, overseeing global operations and reporting directly to the CEO. Mr. Balachandran held senior operations positions at Burroughs Wellcome Co. Mr. Balachandran holds an MBA from East Carolina University, a MS in Chemical Engineering from the State University of New York at Buffalo, and a bachelor’s degree in chemical engineering from The Indian Institute of Technology, Mumbai.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
Who is Madhavan Balachandran and why was he elected to Replimune's Board of Directors?
What is Madhavan Balachandran's professional background?
How might Madhavan Balachandran's election impact Replimune's (REPL) future plans?
When was Madhavan Balachandran elected to Replimune's (REPL) Board of Directors?
